Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Addex Therapeutics Ltd
Addex Therapeutics Ltd News
Addex Therapeutics Ltd Quantitative Score
About Addex Therapeutics Ltd
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Addex Therapeutics Ltd Earnings & Revenue
Addex Therapeutics Ltd Financials
Table Compare
Compare ADXN metrics with: | |||
|---|---|---|---|
Earnings & Growth | ADXN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ADXN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ADXN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ADXN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Addex Therapeutics Ltd Income
Addex Therapeutics Ltd Balance Sheet
Addex Therapeutics Ltd Cash Flow
Addex Therapeutics Ltd Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Addex Therapeutics Ltd Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Addex Therapeutics Ltd Executives
| Name | Role |
|---|---|
| Mr. Timothy Mark Dyer | Co-Founder, Chief Executive Officer & Director |
| Dr. Roger G. Mills M.D. | Chief Medical Officer & Director |
| Mr. Lénaic Teyssédou | Head of Finance |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Timothy Mark Dyer | Co-Founder, Chief Executive Officer & Director | Male | 1968 | -- |
| Dr. Roger G. Mills M.D. | Chief Medical Officer & Director | 1957 | -- | |
| Mr. Lénaic Teyssédou | Head of Finance | Male | 1986 | -- |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science | 1967 | -- |